To assess whether the genetic architecture of this severe therapy-resistant SCZ phenotype differs from the broad DSM-based SCZ phenotype.
ID
Bron
Verkorte titel
Aandoening
Genetics of clozapine use because of schizophrenia, schizo-affective disorder, schizophreniform disorder
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
First, in a discovery cohort a case-control genome-wide association study (GWAS) will be performed on 2000 CLZ using subjects (cases) and >30,000 already available SCZ patients (controls, drawn from the most recent Psychiatric Genomics Consortium analysis, . We hereby aim to reveal potential differences in the genetic architecture between the severe CLZ-SCZ phenotype and the broad SCZ phenotype.
Achtergrond van het onderzoek
Clozapine (CLZ) is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement, thereby implying that patients on CLZ generally suffer from more severe and/or persistent symptoms than patients suffering from schizophrenia spectrum disorders (SCZ) on other antipsychotic agents. Unraveling the (functional) genetic variation underlying this severe SCZ phenotype therefore has the potential to deepen our understanding of the biological underpinnings of SCZ beyond the boundaries of DSM-based consensus criteria. Such knowledge in turn has the potential to shape future pharmacotherapeutic research. We here hypothesize that targeting this phenotype in genome-wide association studies and next-generation sequencing studies will signal genetic risk loci implicated in this severe SCZ phenotype. In the future, this may lead to early detection of severe SCZ, which in turn will enable tailoring of pharmacotherapeutic strategies to such SCZ subtypes.
In addition, we use the data with our other protocol (NTR 5257) to create a prediction model for clozapine response and side effects.
Doel van het onderzoek
To assess whether the genetic architecture of this severe therapy-resistant SCZ phenotype differs from the broad DSM-based SCZ phenotype.
Onderzoeksopzet
One visit
Onderzoeksproduct en/of interventie
None
Publiek
Marte van der Horst
Heidelberglaan 100
Utrecht 3508 GA
The Netherlands
0887551460
mzvanderhorst@gmail.com
Wetenschappelijk
Marte van der Horst
Heidelberglaan 100
Utrecht 3508 GA
The Netherlands
0887551460
mzvanderhorst@gmail.com
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
-he/she currently uses CLZ
-he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis not otherwise specified
-his/her age must be ≥18 years old
-he/she must be able to speak and read the Dutch language
-he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- admission to a psychiatric unit involuntarily in the context of an ‘inbewaringstelling’ (IBS)
- a history of Parkinson’s disease
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5116 |
| NTR-old | NTR5248 |
| CCMO | NL52726.041.15 |
| OMON | NL-OMON50518 |